Open AccessBosentan and the endothelin system in congestive heart failure
Author(s) -
Ellahham Samer H.,
Choucair Wassim K.,
Charlon Vincent,
Abassi Zaid,
Calis Karim A.
Publication year - 2000
Publication title -
clinical cardiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.263
H-Index - 72
eISSN - 1932-8737
pISSN - 0160-9289
DOI - 10.1002/clc.4960231128
Subject(s) - medicine , bosentan , heart failure , cardiology , endothelin receptor , receptor
The endothelin system appears to play an important role in the pathophysiology of congestive heart failure (CHF). Endothelin receptor antagonists represent a novel class of agents that are being evaluated for their potential benefits in treating various cardiovascular disorders. Bosentan is an orally active endothelin receptor antagonist that has been studied for the treatment of CHF. Early clinical experience with bosentan has confirmed some benefits on hemodynamic parameters in patients with CHF. Its role in slowing the progression of the disease and improving survival remains to be elucidated.